'Stealth' corporate innovation: an emerging threat for therapeutic drug development.
Clicks: 316
ID: 55200
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Star Article
83.3
/100
316 views
253 readers
Trending
AI Quality Assessment
Not analyzed
| Reference Key |
mastellos2019stealthnature
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mastellos, Dimitrios C;Blom, Anna M;Connolly, E Sander;Daha, Mohamed R;Geisbrecht, Brian V;Ghebrehiwet, Berhane;Gros, Piet;Hajishengallis, George;Holers, V Michael;Huber-Lang, Markus;Kinoshita, Taroh;Mollnes, Tom E;Montgomery, Robert A;Morgan, B Paul;Nilsson, Bo;Pio, Ruben;Ricklin, Daniel;Risitano, Antonio M;Taylor, Ronald P;Mantovani, Alberto;Ioannidis, John P A;Lambris, John D; |
| Journal | Nature Immunology |
| Year | 2019 |
| DOI | 10.1038/s41590-019-0503-1 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.